All Clinical Trials
Below is a list of all clinical trials, conducted by several of our specialty service lines. You may filter the list of trials by clicking the "Department" dropdown menu and selecting the area that you want to view or that pertains to you.
Clicking "Learn More" may either take you to more information about our departments that conduct the research, or to the official clinicaltrials.gov page for more information about the trial.
MASTER NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)
Study # APEC1621 Date Opened: 07/31/2017
The Project:Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Study # APEC14B1 Date Opened: 11/03/2015
Prospective Cohort Study to Evaluate Immunologic Response Following COVID-19 Vaccination in Children, Adolescents and Young Adults with Cancer
Study # ACCL21C2 Date Opened: 04/08/2022
Establishing Continuous Cell Lines and Xenografts from Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Study # ABTR04B1 Date Opened: 03/05/2007
A Phase 3 Study of Active Surveillance for Low risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Study # AGCT1531 Date Opened: 05/25/2017
A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
Study # ACNS2021 Date Opened: 07/13/2021
A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND #149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors
Study # ACCL2031 Date Opened: 05/10/2022
A Phase 2 Study of Blinatumomab (NSC# 765986, IND #147294) in Combination with Nivolumab (NSC# 748726, IND# 147294), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥ 1 to <31 Years Old with First Relapse
Study # AALL1821 Date Opened: 12/04/2020
COMPLETED - Pediatric Hydroxyurea Phase III Clinical Trial (randomized double-blind placebo Controlled trial of hydroxyurea therapy in very young children) (BABYHUG)
Study # NCT00006400 Date Opened: 08/01/2000
COMPLETED - Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)
Study # NCT00890396 Date Opened: 09/01/2008
COMPLETED - Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol (BABY HUG)
Study # NCT01783990 Date Opened: 10/01/2012
COMPLETED - Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial (SIT)
Study # NCT00072761 Date Opened: 12/01/2004
COMPLETED - Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sick
Study # NCT01737814 Date Opened: 05/01/2013
COMPLETED - Stroke Prevention Trial in Sickle Cell Anemia (STOP II)
Study # NCT00006182 Date Opened: 07/09/2000
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)”
A191901: OPTIMIZING ENDOCRINE THERAPY THROUGH MOTIVATIONAL INTERVIEWING AND TEXT INTERVENTIONS
INTEGRATED CANCER REPOSITORY FOR CANCER RESEARCH (iCaRe2)
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Pa
